Normal cells limit damage to healthy tissue
Inactivation of T cells limits damage to healthy tissue.
Tumor cell escapes detection
Blocking CTLA-4 contributes to an increase in anti-tumor immune response.
CTLA-4 therapy augments T cell activation and proliferation
Blocking CTLA-4 contributes to an increase in anti-tumor immune response.
PD-1 therapies harness the immune response to fight tumors
Blocking PD-1 enables cytotoxic T cells to actively remove tumor cells.
Want to hear more about PD-L1 IHC 28-8 pharmDx?
Contact your local sales representative